Epithalon

Overview

Mechanisms

Evidence

  • [literature-animal] Mimics pineal epithalamin; animal data: telomere lengthening, tumor suppression, circadian/melatonin recalibration, anti-inflammatory. Telomere↔longevity link controversial; no human trials — lifespan claims are a leap. — Huberman 01:06–01:12

  • [literature-animal] Mouse retinal-neuroprotection (retinitis pigmentosa, glaucoma) via DNA-repair / genetic-machinery support; Bakri hypothesises melanopsin upregulation (enhancing morning-light signalling). — Bakri 01:25–01:27

  • [educational] Ranked #2 longevity — restores pineal melatonin/circadian + antioxidant + DNA/epigenetic stabilization + telomere lengthening. Preclinical lifespan: epitalon +11–16% flies, +12.3% max in mice, 6× ↓leukemia; epithalamin extract +11–31% mice / +25% rats; human data only for epithalamin (Russian mortality ↓1.6–2.5×). — Longevity Top-5

Anecdotes

  • [anecdote] Russian bioregulator used for circadian rhythm; involved in DNA repair; explored in animal studies for retinal degeneration. [note] On the FDA do-not-compound list. — Koniver 01:27

  • [literature-russian] Tripeptide AEDG from the pineal, mimics endogenous epithalamin; restores melatonin in aged (not young) animals; normalises clock genes + morning cortisol. Khavinson’s 15-yr nursing-home study (epithalamin + thymalin, ~10–20 days/yr) reported lower CVD/infection/cancer mortality. — Bakri 01:22–01:24

  • [anecdote-bb] Community anti-aging dosing: ‘Ukrainian’ ~50 mg / ‘Russian’ ~100 mg every ~6 months (telomerase rationale; effect unverifiable for years). Astragaloside IV cited as a cheaper telomerase-activation alternative. — Anabolic Roundtable ~01:30–01:36

Physician protocols

Practical notes

  • [regulatory] US status shifting (2026): the “FDA do-not-compound list” note above is now dated — Epitalon was removed from Category 2 (Feb 2026) and is on the FDA PCAC 503A agenda for July 24 2026 (use evaluated: insomnia). Advisory/non-binding; not FDA-approved. — SOURCE-fda-pcac-503a-peptide-review-2026